Lamivudine and Plasma Markers of Inflammation in Retinal Detachment
Intra-ocular Penetration of Oral Lamivudine and Measurement of Systemic Inflammatory Markers in Patients Undergoing Rhegmatogenous Retinal Detachment Surgery
Sponsor: University of Wisconsin, Madison
Terminated
Treatment approach changed, and insufficient population
Other terminated trials from University of Wisconsin, Madison
Other Retinal Detachment trials with similar outcome
A EARLY_PHASE1 clinical study on Retinal Detachment and Rhegmatogenous Retinal Detachment, this trial is terminated or withdrawn. The trial is conducted by University of Wisconsin, Madison and has accumulated 9 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Oct 2024 — Present [monthly]
Terminated EARLY_PHASE1
Status: Recruiting → Terminated
-
Sep 2024 — Oct 2024 [monthly]
Recruiting EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting EARLY_PHASE1
-
Mar 2024 — Jun 2024 [monthly]
Recruiting EARLY_PHASE1
▶ Show 4 earlier versions
-
Feb 2024 — Mar 2024 [monthly]
Recruiting EARLY_PHASE1
-
Jan 2024 — Feb 2024 [monthly]
Recruiting EARLY_PHASE1
-
Dec 2023 — Jan 2024 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2023 — Dec 2023 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Wisconsin, Madison
For direct contact, visit the study record on ClinicalTrials.gov .